GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Mesoblast MESO · USD

Health Care · US listing · 🇺🇸 United States

Compare

14.44

+1.19%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$120.3m

FY2017FY2026

Net income

−$57.5m

FY2017FY2026

Free cash flow

—

FY2017FY2026

Shareholders' equity

$568.4m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$120.3m$17.2m$5.9m$7.5m$10.2m$7.5m$32.2m$16.7m$17.3m$2.4m
Research and development$97.5m$34.8m$25.4m$27.2m$32.8m$53.0m$56.2m$59.8m$65.9m$58.9m
Operating income−$51.3m−$62.4m−$69.3m−$62.8m−$81.0m−$88.9m−$72.6m−$87.0m−$77.3m−$90.0m
Net income−$57.5m−$102.1m−$88.0m−$81.9m−$91.3m−$98.8m−$77.9m−$89.8m−$35.3m−$76.8m
Diluted earnings per share-0.04-0.79-0.77-0.96-1.19-1.52-1.33-1.68-0.72-1.63

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$773.1m$784.7m$669.2m$669.4m$662.1m$744.7m$733.6m$652.1m$692.4m$655.7m
Cash and short-term investments—$161.2m$62.6m$70.9m$60.0m$136.9m$129.3m$50.4m$37.8m$45.8m
Total liabilities$204.7m$187.2m$188.8m$167.6m$165.1m$163.3m$184.3m$171.1m$146.4m$138.9m
Debt$108.6m$124.6m$117.0m$112.8m$99.8m$97.0m$93.0m$81.3m$118.8m—
Shareholders' equity$568.4m$597.4m$480.4m$501.8m$497.0m$581.4m$549.3m$481.1m$546.0m$516.8m
Shares outstanding1,295m129m114m85m77m65m59m53m49m47m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations—−$50.0m−$48.5m−$63.3m−$65.8m−$106.7m−$56.4m−$57.8m−$75.0m−$95.5m
Capital spending−$898,000−$730,000−$331,000−$314,000−$232,000−$1.6m−$2.2m−$279,000−$201,000−$311,000
Free cash flow—−$50.7m−$48.8m−$63.6m−$66.0m−$108.3m−$58.6m−$58.1m−$75.2m−$95.8m

Latest quarters

By quarter end

Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
Revenue$25.7m$25.7m$7.0m$7.0m$1.6m$1.6m$1.3m$1.3m
Operating income−$38.6m−$38.6m−$34.4m−$34.4m−$20.6m−$20.6m−$22.0m−$22.0m
Net income−$20.1m−$20.1m−$27.1m−$27.1m−$24.0m−$24.0m−$27.7m−$27.7m
Diluted earnings per share-0.16-0.16-0.21-0.21-0.21-0.21-0.24-0.24
Cash from operations−$15.0m−$14.0m−$16.0m−$12.0m−$10.0m−$10.0m−$10.0m−$11.0m
Total assets$782.3m$782.3m$784.7m$784.7m$653.3m$653.3m$669.2m$669.2m
Cash and short-term investments$129.6m$130.0m$161.2m$161.6m$38.0m$38.0m$62.6m$63.0m
Debt$129.3m$69.1m$124.6m$56.8m$121.4m$19.9m$117.0m$16.5m
Shareholders' equity$574.7m$574.7m$597.4m$597.4m$461.3m$461.3m$480.4m$480.4m

Financial ratios

Data as of 31 Oct 2026

FY2026FY2025FY2024FY2023FY2022FY2021
Operating margin-42.6%-465.5%-982.2%-835.3%-792.8%-1192.5%
Net margin-47.8%-593.9%-1490.3%-1091.7%-894.6%-1325.3%
Return on equity-10.2%-17.1%-18.3%-16.3%-18.4%-17.0%
Return on assets-7.5%-13.0%-13.1%-12.2%-13.8%-13.3%
Free cash flow yield-2.2%-2.5%-2.8%-4.9%-5.6%-10.7%
Revenue growth602.3%191.4%-21.3%-26.5%37.0%-76.8%
Earnings growth-43.5%16.1%7.4%-10.4%-7.6%26.8%
Current ratio2.43x1.99x1.18x1.95x1.36x1.57x
Debt to equity0.22x0.21x0.24x0.22x0.20x0.17x
Equity ratio73.5%76.1%71.8%75.0%75.1%78.1%
Interest coverage-2.15x-3.49x-2.81x-3.22x-4.68x-8.30x
R&D as a share of sales81.1%202.4%429.6%362.5%321.4%711.0%
Buybacks as a share of market value-0.4%-13.1%-34.2%-10.5%-18.9%-10.5%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue152.1%74.4%10.9%
Operating income-6.6%-10.4%-4.5%
Net income-11.1%-10.3%30.1%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-82.7%-163.0%-246.7%-294.7%
Net margin-116.1%-218.4%-308.4%-287.3%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-321.9-22.8-25.7-2.3-2.0-2.6-5.3-2.3-3.0-1.9
Price to sales153.9135.5383.225.018.134.312.712.56.260.7

Market value over time

30 Nov 2016 to 30 Oct 2026, in USD

$339.6m$1.97bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return52%478%-15%-36%-45%92%84%-34%13%36%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 2-to-1 reverse split · 10 Jan 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.